Indegene Q2 net profit rises 11% to ₹102 crore on strong revenue growth

Healthcare tech firm Indegene Ltd on Thursday (October 30) reported an 11.34% year-on-year increase in net profit to ₹102.1 crore for the quarter ended September 2025, compared with ₹91.7 crore in the same period last year. Revenue from operations rose 17.1% year-on-year to ₹804.2 crore from ₹686.8 crore.

The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) grew 11.7% to ₹140.8 crore compared to ₹126.1 crore a year earlier. However, the operating margin declined to 17.5% from 18.4% in the corresponding quarter of the previous year.

Indegene has announced an investment in its wholly owned subsidiary, Indegene Ireland Ltd, to support the unit’s capital expenditure requirements aimed at expanding its business operations. The investment will be completed by December 31, 2026, the company said.

Also Read: Indegene sees growth tailwinds from digital pharma shift, boosts US presence with BioPharm deal

Indegene Ireland Ltd provides analytics, technology, and commercial, medical, regulatory, and safety solutions to life science and healthcare organisations. For the financial year ended March 31, 2025, the subsidiary reported a turnover of €739,163. Its turnover for the previous financial years stood at €477,388 in FY23 and €596,780 in FY24.

The investment will be made in cash, with Indegene subscribing to equity shares of €1 face value each at a premium to be determined based on a valuation report by a registered valuer.

Shares of Indegene Ltd ended at ₹551.05, up by ₹4.50, or 0.82%, on the BSE.

Also Read: Indegene Block Deal: CA Dawn Investments likely to offload 10.2% stake worth ₹1,420 crore